TRAIL is an apoptosis-inducing ligand constitutively expressed on liver-resident type 1 innate lymphoid cells (ILC1s) and a subset of natural killer (NK) cells, where it contributes to NK cell antitumor, anti-viral, and immunoregulatory functions. However, the intrinsic pathways involved in TRAIL expression in ILCs remain unclear. Here, we demonstrate that the murine natural cytotoxic receptor mNKp46/NCR1, expressed on ILC1s and NK cells, controls TRAIL protein expression. Using NKp46-deficient mice, we show that ILC1s lack constitutive expression of TRAIL protein and that NK cells activated in vitro and in vivo fail to upregulate cell surface TRAIL in the absence of NKp46. We show that NKp46 regulates TRAIL expression in a dose-dependent manner and that the reintroduction of NKp46 in mature NK cells deficient for NKp46 is sufficient to restore TRAIL surface expression. These studies uncover a link between NKp46 and TRAIL expression in ILCs with potential implications in pathologies involving NKp46-expressing cells.
NO MEMBRANE TRAIL

SUMMARY
TRAIL is an apoptosis-inducing ligand constitutively expressed on liver-resident type 1 innate lymphoid cells (ILC1s) and a subset of natural killer (NK) cells, where it contributes to NK cell antitumor, anti-viral, and immunoregulatory functions. However, the intrinsic pathways involved in TRAIL expression in ILCs remain unclear. Here, we demonstrate that the murine natural cytotoxic receptor mNKp46/NCR1, expressed on ILC1s and NK cells, controls TRAIL protein expression. Using NKp46-deficient mice, we show that ILC1s lack constitutive expression of TRAIL protein and that NK cells activated in vitro and in vivo fail to upregulate cell surface TRAIL in the absence of NKp46. We show that NKp46 regulates TRAIL expression in a dose-dependent manner and that the reintroduction of NKp46 in mature NK cells deficient for NKp46 is sufficient to restore TRAIL surface expression. These studies uncover a link between NKp46 and TRAIL expression in ILCs with potential implications in pathologies involving NKp46-expressing cells.
INTRODUCTION
Natural killer (NK) cells are innate lymphoid cells able to discriminate and eliminate infected cells and tumor cells because of a large panel of germline-encoded receptors (Biassoni et al., 2001; Lanier, 2005) . The stimulatory receptor NKp46 is one of the natural cytotoxic receptors (NCRs) expressed on all NK cells (Pessino et al., 1998) . It efficiently triggers the release of cytotoxic granules, cytokines, and chemokines upon binding ligands of viral (Mandelboim et al., 2001) , bacterial (Vankayalapati et al., 2002) , and cellular origin (Narni-Mancinelli et al., 2017) in addition to unidentified ligands on tumor cells (Cagnano et al., 2008) . Human NKp46 and its mouse ortholog NKp46/NCR1 (CD335) (Biassoni et al., 1999) are immunoglobulin (Ig)-like transmembrane glycoproteins. In addition to NK cells, NKp46 is also expressed by type 1 innate lymphoid cells (ILC1s) (Cortez and Colonna, 2016; Zook and Kee, 2016) , a subset of group 3 ILCs (Montaldo et al., 2015) and a small subset of T cells. NKp46-deficient mice (Ncr1 gfp/gfp ) have been widely used to demonstrate the importance of NKp46 in the control of microbial infection (Gazit et al., 2006) and tumor development by NK cells (Glasner et al., 2012) as well as in contributing to type 1 diabetes (Gur et al., 2010) . When activated, NK cell lytic activity is mainly mediated via exocytosis of cytotoxic granules containing a payload predominantly made up of perforin and granzymes. Other pathways include the engagement of death receptors via membrane-bound or soluble proteins that belong to the tumor necrosis factor (TNF) family of cytokines (Falschlehner et al., 2009) . The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) is a type II transmembrane protein (Wiley et al., 1995) constitutively expressed on liver-resident NK cells in humans and in mice (Peng and Tian, 2017; Takeda et al., 2005; Yokoyama et al., 2013) , a population of cells that has recently been categorized as ILC1s (Cortez and Colonna, 2016; Jiao et al., 2016) . In addition to TRAIL, the transcription factors T-bet and Eomesodermin (Eomes) are commonly used to identify resident NK cells in the mouse (Daussy et al., 2014; Gordon et al., 2012) and human liver tissue (Cuff et al., 2016; Harmon et al., 2016) . Other markers include chemokine receptors and integrins of the CD49 antigenlike family (Aw Yeang et al., 2017; Daussy et al., 2014; Gordon et al., 2012) , showing similarities between mouse-and human-resident NK cells described in healthy livers (Marquardt et al., 2015) . These tissue-resident ILC1s have recently been shown to represent a major early source of interferon g (IFN-g), making them important first responders to viral infection (Weizman et al., 2017) Human and mouse TRAIL engage receptors that possess a death domain and induce caspase 8-mediated apoptosis, including TRAIL-R1/DR4 in humans and TRAIL-R2/DR5 in both species (Walczak et al., 1997) . Other receptors include TRAIL-R3 and TRAIL-R4-considered a decoy receptor because of the lack of or incomplete death domain-and the soluble protein Osteoprotegerin, none of which promote cell death (Degli-Esposti, 1999) . TRAIL is a well-established player in anti-tumor immunity, potently clearing TRAIL-R-expressing tumors without affecting normal primary tissue (Walczak et al., 1999) . Indeed, several reports established that TRAIL is involved in NK cell-mediated rejection of transplanted tumors expressing TRAIL-R Takeda et al., 2001) , chemically induced sarcoma (Cretney et al., 2002) , and liver metastases (Cretney et al., 2002; Seki et al., 2003; Smyth et al., 2001 ) as well as hematological malignancies (Zerafa et al., 2005) .
An important and increasingly recognized function of TRAIL is its involvement in the regulatory function of NK cells (Hayakawa et al., 2004) , especially in contexts of virally induced chronic inflammation (Maini and Peppa, 2013; Schuster et al., 2016) . In the well-studied model of mouse cytomegalovirus (MCMV) infection, NK cells can limit the function and antiviral T cell responses via elimination of MCMV-infected dendritic cells (Andrews et al., 2010) and CD4 + T cells (Schuster et al., 2014) . Inflammatory cytokines such as IFNs Stegmann et al., 2010) , interleukin-26 (IL-26) (Miot et al., 2015) , and IL-15 and IL-2 (Kayagaki et al., 1999) 
and Ncr1 À/À mice with poly(I:C) and a-galactosylceramide (a-GalCer), 2 immunogenic compounds known to upregulate TRAIL on NK cells via induction of proinflammatory cytokines Takeda et al., 2005; Tu et al., 2011) . NK cells and ILC1s retrieved from the lymph nodes of poly(I:C)-injected Ncr1 +/+ and Ncr1 À/À mice showed similar expression profiles of the activation marker CD69, indicating comparable activation levels ( Figure 2A (Sheppard et al., 2013) . In addition, expression of the IFN-g receptor (CD119) is equivalent in NK cells from Ncr1
and Ncr1 +/+ mice ( Figure S1 ). Collectively, these data indicate that the inability of NK cells to induce TRAIL in the absence of NKp46 is not due to a defect in NK cell activation.
IL-2 and IL-15 Fail to Upregulate TRAIL on Mature
Mature splenic NK cells in wild-type mice do not express TRAIL unless activated in culture in the presence of IL-2 (Tu et al., 2011) or IL-15 (Kayagaki et al., 1999; Zamai et al., 1998 Figure 3C ). NK cells from Ncr1
and Ncr1 À/À mice expressed equivalent levels of the IL-2 receptor a chain (CD25) and the b (CD122) and g chains (CD132) shared by the IL-2 and IL-15 receptors ( Figure S1 ). Thus, the differences in the induction of TRAIL expression were not the result of differential signaling through these receptors. Interestingly, we observed a positive correlation between NKp46 and TRAIL expression in Ncr1 +/+ mice, dependent on the concentration of IL-15 present in the culture. Low levels of IL-15 (10 ng/mL) induced high levels of NKp46 and TRAIL that diminished with increasing concentrations of IL-15 ( Figure 3D ).
Because a small fraction of NKp46-deficient NK cells seems to be weakly positive for TRAIL when assessed via flow cytometry (shoulder positivity), we employed ImageStream to visualize TRAIL at the cell membrane, using NK1.1 expression as positive control. Figure 3E shows that the faint TRAIL staining seen in NKp46-deficient NK cells (bottom) was similar to the signal detected by isotype staining (center) and significantly lower than TRAIL low and TRAIL hi staining in NK cells from wild-type mice (top) ( Figure S2 ). We conclude that TRAIL is mainly absent from NKp46-deficient NK cells, although we cannot totally exclude that a very low amount of TRAIL spontaneously reaches the surface of NKp46-deficient NK cells.
To gain further insight into the stage of TRAIL regulation by NKp46, we quantified the amount of Tnfsf10 transcripts coding for TRAIL in sorted NK cells cultured in the presence of IL-15 for 5 days. Similar levels of Tnfsf10 mRNA were detected in NK cells from Ncr1 +/+ and Ncr1 À/À mice, indicating that NKp46
does not control gene transcription or the stability of Tnfsf10 mRNA ( Figure 3F ). This was further shown in liver ILC1s where equal amounts of Tnfsf10 transcripts were detected in both strains ( Figure S3 ). Western blotting of TRAIL in activated NK cells revealed that the protein was expressed in the presence or absence of NKp46 ( Figure 3G ), which was confirmed by intracellular detection of TRAIL in NKp46-deficient NK cells ( Figure 3H ). Collectively, these data show that NKp46 controls TRAIL protein expression at a post-translational level by affecting its trafficking to the membrane.
NKp46 Is Sufficient to Restore TRAIL Surface Expression in Ncr1 À/À NK Cells
To determine whether NKp46 is sufficient to induce TRAIL surface expression, we transduced primary NK cells isolated from Ncr1 À/À mice with an Ncr1-expressing vector. The reintroduction of NKp46 restored TRAIL expression in NKp46-deficient NK cells ( Figures  4A and 4B) . Remarkably, the level of TRAIL and NKp46 expression after transfection positively correlated with the NKp46 low NK subset expressing lower levels of TRAIL compared with the NKp46 hi subset ( Figure 4B ). This result is consistent with those obtained using IL-15-activated NK cells ( Figure 3D ). In conclusion, our data show that NKp46 is sufficient to control TRAIL surface expression in a dose-dependent manner.
DISCUSSION
In this study, we describe an unexpected link between murine NKp46 and the death-inducing ligand TRAIL, proteins that are coexpressed by ILC1s and NK cells. Analysis of the NKp46-deficient mouse revealed that ILC1s and small subsets of immature NK cells lack TRAIL membrane expression at steady state in an otherwise normal immune context (Sheppard et al., 2013) . These data indicate that impaired TRAIL expression in the Ncr1 À/À mouse is caused by the lack of NKp46 and not by developmental defects in the ILC compartment. In addition, in the absence of NKp46, mature NK cells activated in vitro and in vivo fail to upregulate cell surface TRAIL unless NKp46 is transduced. We demonstrate that NKp46 is necessary for TRAIL surface expression and that this likely involves a cell-intrinsic regulatory mechanism.
This phenotype raises several key questions with regards to the mechanism(s) involved. First, how is NKp46 controlling TRAIL expression? NKp46 likely affects TRAIL trafficking to the membrane because we detected a comparable amount of transcripts encoding TRAIL and cytosolic protein in NKp46-deficient and -sufficient NK cells. Possible mechanisms include a requirement for NKp46 to release TRAIL from cytoplasmic vesicles and/or to act as a chaperone for TRAIL localization to the plasma membrane. Co-localization studies of TRAIL and NKp46 via (Westgaard et al., 2004) . Studies examining TRAIL expression in NK cells selectively modified in this region and thus defective in NKp46 signaling will provide critical mechanistic insights. Moreover, the Noe´mouse is a valuable model that might help address the requirement for NKp46 to bind extracellular ligands because the mouse has impaired NKp46 surface expression (Narni-Mancinelli et al., 2012) but retains cytoplasmic NKp46 (Glasner et al., 2015; Narni-Mancinelli et al., 2012) . Additional questions arise from the fact that other cell types that do not express NKp46, including monocytes (Ellis et al., 2015) and T cells (Ishikawa et al., 2005) , can exhibit cell surface TRAIL expression upon infection, findings that imply that NKp46-mediated control of TRAIL may be specific to the ILC compartment.
With regards to the biological relevance of TRAIL regulation by NKp46, both proteins are known players in anti-tumor responses (Koch et al., 2013; Seki et al., 2003; Walczak et al., 1999) ; hence, the concomitant expression of NKp46 and TRAIL is likely to potentiate NK cell direct killing activity against tumors bearing NKp46 ligands and TRAIL receptors. Also, TRAIL/TRAIL-R is a critical axis of immunoregulation by NK cells upon persistent infection (Schuster et al., 2014) . The constitutive expression of TRAIL on resident hepatic NK cells and upregulation via inflammatory cytokines likely contribute to maintaining an immunosuppressive environment characteristic of the liver tissue and avoiding hepatitis upon prolonged cytokine exposure. Peppa et al. (2013) previously demonstrated that TRAIL + NK cells contribute to persistent infection and liver damage by eliminating hepatitis B virus (HBV)-specific CD8 + T cells that upregulate TRAIL-R2, thereby becoming susceptible to TRAIL-mediated apoptosis . Recently, Yoshioka et al. (2017) observed a higher frequency of NKp46 in HBV-infected patients with a high viral DNA titer compared with healthy subjects, which correlated with high levels of alanine transaminase (ALT), a hallmark of liver damage (Yoshioka et al., 2017) . The authors showed that a subset of NKp46 hi NKG2A hi NK cells displays an elevated level of TRAIL mRNA and a high cytotoxic potential against activated T cells in vitro (Yoshioka et al., 2017) . Hence, it is plausible that NKp46 and TRAIL act in concert to target TRAIL-R-expressing immune cells upon persistent inflammation in HBV-infected patients. Similarly, NKp46-deficient mice were used to demonstrate that NK cells can attenuate liver fibrosis via NKp46-mediated killing of hepatic stellate cells (HSCs) that express NKp46 ligands (Gur et al., 2011) ; TRAIL could potentially be involved in the protective role of NK cells in this model. NK cells can also participate in tissue damage in the context of persistent inflammation. NK cells contribute to TRAIL-mediated apoptosis of hepatocytes isolated from HBV-infected individuals, suggesting that TRAIL + NK cells have the potential to promote liver damage (Dunn et al., 2007) . Similarly, NK cells have been involved in the pathogenesis of autoimmune diseases such as type 1 diabetes. There is a high frequency of activated NKp46 + NK cells in diabetic patients (Wang et al., 2015) , and NKp46 ligands are detected on human and mouse pancreatic b cells, with the ability to induce NKp46-mediated NK cell degranulation (Gur et al., 2010) . Compared with the NKp46-sufficient mouse, NKp46-deficient mice developed low-dose-ofstreptozotocin (LDST)-induced type 1 (T1) diabetes at a lower frequency and displayed lower blood glucose levels, demonstrating the role of NKp46 in the development of diabetes (Gur et al., 2010) . TRAIL could be involved in the NKp46-mediated NK cell response in this model. Indeed, it is known that the normal human pancreas exhibits a high amount of TRAIL-R under chronic inflammatory conditions such as chronic pancreatitis (Hasel et al., 2003) ; hence, NK cells could be deleterious via both NKp46/NKp46 ligands and TRAIL/TRAIL-R interactions.
In conclusion, several phenotypes based on studies of the NKp46-deficient mouse may actually arise because of the concomitant lack of TRAIL and NKp46 expression. The relationship between NKp46 and TRAIL described here should be taken into consideration when reflecting on past studies of the Ncr1 À/À mouse and on future studies addressing NKp46 and TRAIL functions.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in the Supplemental Information.
Animals
Ncr1
gfp/gfp mice (RRID:IMSR_JAX:022739), kindly provided by Prof. Ofer
Mandelboim (Gazit et al., 2006) , were bred and maintained in the animal facility at Imperial College London in a specific pathogen-free environment. Work was carried out in compliance with the British Home Office Animals Scientific Procedures Act 1986 (PPL70/7129).
NK Cell Isolation, Activation, and Transduction NK cells were activated in vitro in complete RPMI medium supplemented with IL-2 or IL-15 as indicated in the figure legends. 2 mg of a-GalCer (intraperitoneally [i.p.]) or 100 mg of poly(I:C) was used to activate NK cells in vivo. 293T cells were transfected with the vesicular stomatitis virus G protein (VSV-G)-pseudotyped lentiviral vector SIN18-RhMLV-Cppt-2E (Tran and Kung, 2007) containing GFP or Ncr1 using TransIT-293 (Mirus). NK cells that had been cultured for 3 days in 1,000 U/mL IL-2 were transduced with viral particles containing supernatant and assessed for TRAIL and NKp46 expression by flow cytometry.
RNA Isolation and Real-Time qPCR
Reverse-transcribed cDNA was amplified using the TaqMan PreAmp Master Mix Kit prior to real-time qPCR (TaqMan system, Applied Biosystems). All values were normalized to Gapdh expression.
Western Blotting
Total cell lysate transferred to a polyvinylidene fluoride (PVDF) membrane was immunoblotted with either anti-TRAIL or anti-actin antibodies prior blot analysis (Image Lab software, Bio-Rad).
ImageStream
Primary splenocytes were stained for the indicated markers and analyzed on ImageStreamX Mark II (Amnis, USA) and analyzed using IDEAS software.
Statistical Analyses
Two-tailed unpaired Student's t test and Mann-Whitney tests were applied (as indicated in the figure legends) when appropriate (GraphPad). Differences at p % 0.05 were considered significant: *p % 0.05, **p % 0.01, ***p % 0.001, ****p % 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes STAR Methods and three figures and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.03.023.
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